Prepared by controlled thawing of frozen plasma to precipitate higher molecular weight proteins.
A blood component created by thawing units of fresh frozen plasma at 1°C to 6°C and collecting the precipitated proteins by centrifugation.
Contains fibrinogen, fibronecton, platelet microparticles, factor VIII, factor XIII and von Willebrand factor and is usually given for hypofibrinogenmia, dysfibrinogenemia and factor XIII deficiencies.
Utilized for a concentrated source of fibrinogen, and is the only intravenous source of adequate fibrinogen available.
Its fibrinogen content varies widely from 3-30 g/L per unit.
It is usually supplied in five unit pools of approximately 100 mL.
It contains a concentration of fibrinogen similar to that of reconstituted fibrinogen concentrate but also contains fibronectin, von Willebrand factor, factor VIII, and factor XIII.
It must be maintained and shipped in a frozen state then thawed and pooled, typically 5-10 unit pools before administration.
Requires 2-10 minutes to thaw after ordering.
It is 4-10 times less expensive per gram of fibrinogen than fibrinogen concentrate.
It has a limited shelflife after thawing of 4-6 hours, increasing wastage.
Available as pre-pooled concentrates of six units.
10 bags of cryoprecipitate can raise plasma fibrinogen level by 1 gm/L, 60-100 mg/dL.
Utilized in liver disease, following cardiovascular surgery, reversal of warfarin, with DIC, following massive transfusion treatment and with TTP.
Compatibilty testing not necessary but given as ABO compatible when possible.
Its compatibility is reversed for plasma products : AB is the universal donor and O type is the universal plasma recipient.
Each 15 mL typically contains 100IU of factor VIII, and 250 mg of fibrinogen.
Should have an average of 150 mg of fibrinogen and 80 IU of factor VIII.
Aside from infants it is rare to transfuse 1 u, and is usually given as 4-6 unit pools.
Indications: hemophilia when factor concentrates are not available, von willebrand’s disease (Not currently recommended), hypofibrinogenemia associated with massive transfusion, bleeding when excessive anticoagulation is present (FFP is a better choice), massive hemorrhage although RBCs and volume expanders are better, and DIC.
Indicated for prophylaxis or bleeding when significant hypofibrinogen is present
1 bag contains about 350 mg of fibrinogen.
Recovery with transfusion is about 75%
Six bags can raise the fibrinogen level by about 45 mg/dL.
Approximately 150 units of factor VIII and von Willebrand factor are provided per bag.
FIBRES trial was a multi center, single blind, randomized, controlled, non-inferiority clinical trial of fibrinogen concentrate versus cryoprecipitate in patients undergoing cardiac surgery and experiencing major bleeding: The study showed that fibrinogen concentrates was non-inferior to cryoprecipitate.